Stoke (STOK) - Forward P/S Multiple
Stoke Therapeutics (STOK) is utilizing its oligonucleotide synthesis capacities to the maximum to adhere to trial schedules. The issuer's forward P/S helps filter out market noise, with the value holding at 60.40. Drug development is accelerating through AI modeling and automation. The business is anchored by the TANGO platform, which creates a closed therapeutic loop by managing gene expression.
Metric breakdowns and analytics for Stoke Corp (STOK)
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Stoke Therapeutics|STOK - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Stoke Therapeutics|STOK - Company Cumulative Indebtedness|Debts to Book Capitalization Stoke Corp|STOK - Long-Term Debt Volume|Company Short-Term Debts Stoke Therapeutics|Quick Liquidity stoketherapeutics.com
- business earnings and investment ratios data:
STOK - Net Financial Result|Expected Profit Stoke Therapeutics|STOK - Business Payback Period|Projected Price to Earnings Stoke|STOK - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stoke Corp|STOK - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Stoke Therapeutics|STOK - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth stoketherapeutics.com|STOK - Earnings per share growth this year|Net earnings per share growth forecast for next year Stoke Therapeutics
- sales volume and revenue information:
General company analysis:Stoke Therapeutics, Inc. STOK
For Stoke Therapeutics (STOK), which is developing breakthrough RNA therapy for Dravet syndrome, changes in the forward P/S ratio serve as an indicator of market expectations regarding pipeline commercialization. This multiple compares current market capitalization with projected revenue for future periods. It measures the premium for scientific potential, reflecting the value of each unit of expected sales. A decline in this metric may indicate an undervalued asset or increasing risks associated with the execution of clinical trials.
Analysis of competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|RGEN - Forward P/S Multiple|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CRSP (crisprtx.com)|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Forward P/S Multiple Sarepta Corp (SRPT)|Twist Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio BioLife Solutions Inc BLFS|WVE: Forward P/S Multiple|Forward Price-to-Revenue Multiple Maze Therapeutics Corp|Price-to-Projected Revenue Ratio Sionna Therapeutics Inc|primemedicine.com (PRME) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Market Cap to Expected Sales Ratio uniQure NV|MeiraGTx PLC - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio RGNX (REGENXBIO Corp)|SLDB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio ocugen.com|PacBio (PACB) - Price-to-Projected Revenue Ratio|Benitec Biopharma Inc (BNTC) - Forward P/S Multiple|DSGN (Design Pharma) - Forward P/S Multiple|Market Cap to Projected Revenue RCKT (Rocket Corp)|Price-to-Projected Revenue Ratio 4D Molecular Therapeutics (FDMT)|lexeotx.com - Market Cap to Projected Revenue|Forward P/S Multiple KRRO (Korro Bio)|Forward P/S Multiple Editas Medicine Inc EDIT|SLN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio ProQR Therapeutics N.V. PRQR|CDXS (codexis.com) - Forward Price-to-Revenue Multiple|SGMO: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Future Revenue Ratio Metagenomi Inc. MGX|Price-to-Projected Revenue Ratio Precision BioSciences, Inc. (DTIL)|Forward P/S Multiple generationbio.com (GBIO)|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Exicure Inc. (XCUR) - Market Cap to Future Revenue Ratio|IMNN: Forward Price-to-Revenue Multiple|Forward Price to Sales PHIO (Phio Pharmaceuticals)|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|RNAZ: Price to Expected Revenue Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|APDN: Forward Price to Sales|Forward P/S Multiple BLUE|IPA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omega OMGA|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS - Forward P/S Multiple|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Forward P/S Multiple
